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OBJECTIVES The aim of this study was to derivate and validate a prediction model for cardiovascu-
lar events based on quantiﬁcation of coronary and aortic calcium volume in lung cancer screening chest
computed tomography (CT).
BACKGROUND CT-based lung cancer screening in heavy smokers is a very timely topic. Given that
the heavily smoking screening population is also at risk for cardiovascular disease, CT-based screening
may provide the opportunity to additionally identify participants at high cardiovascular risk.
METHODS Inspiratory screening CT of the chest was obtained in 3,648 screening participants. Next,
smoking characteristics, patient demographics, and physician-diagnosed cardiovascular events were
collected from 10 years before the screening CT (i.e., cardiovascular history) until 3 years after the
screening CT (i.e., follow-up time). Cox proportional hazards analysis was used to derivate and validate
a prediction model for cardiovascular risk. Age, smoking status, smoking history, and cardiovascular his-
tory, together with automatically quantiﬁed coronary and aortic calcium volume from the screening CT,
were included as independent predictors. The primary outcome measure was the discriminatory value of
the model.
RESULTS Incident cardiovascular events occurred in 145 of 1,834 males (derivation cohort) and 118
of 1,725 males and 2 of 89 females (validation cohort). The model showed good discrimination in the
validation cohort with a C-statistic of 0.71 (95% conﬁdence interval: 0.67 to 0.76). When high risk was
deﬁned as a 3-year risk of 6% and higher, 589 of 1,725 males were regarded as high risk and 72 of
118 of all events were correctly predicted by the model.
CONCLUSIONS Quantiﬁcation of coronary and aortic calcium volumes in lung cancer screening CT
imagesdinformation that is readily availabledcan be used to predict cardiovascular risk. Such an
approach might prove useful in the reduction of cardiovascular morbidity and mortality and may
enhance the cost-effectiveness of CT-based screening in heavy smokers. (J Am Coll Cardiol Img
2013;6:899–907) ª 2013 by the American College of Cardiology Foundation
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ardiovascular disease is a major cause of
mortality in heavy cigarette smokers. In the
NLST (National Lung Cancer Screening
Trial) trial most participants died from car-
diovascular disease (1), which conﬁrms observations
in other cohorts (2,3). The NLST achievement is
remarkable as this is the ﬁrst cancer screening trial
demonstrating an all-cause mortality reduction. This
raises high expectations for chest computed tomog-
raphy (CT)–based lung cancer screening (1,4).
Nevertheless, CT-based screening for lung cancer
will be costly and may therefore not be adopted by
many countries (5).
It has recently been shown that CT-based
screening can aid in the automatic identiﬁcation of
additional subjects with chronic obstructive pulmo-
nary disease (6). Interestingly, the test that is used for
lung cancer screening (i.e., CT), is also suitable for
quantiﬁcation of vascular calciﬁcations, which are
strong predictors for cardiovascular events in multiple
other settings (7–12). Because cardiovascular
morbidity and mortality can be reduced through pri-
mary and secondary preventive efforts (13,14), inclu-
sion of cardiovascular disease in the screening protocol
may enhance the beneﬁts and the cost-
effectiveness of chest CT-based screening
of heavy smokers. However, it is currently
unknown how well lung cancer screening
chest CT can predict cardiovascular events.
In this study, we developed and vali-
dated a prediction model using the extent of coro-
nary and aortic calciﬁcations quantiﬁed in lung
cancer screening chest CT scans to predict cardio-
vascular events and re-events.
METHODS
Ethics statement. This present study is an ancil-
lary study of the population-based NELSON
(NEderlands Leuvens Longkanker Screenings
ONderzoek; ISRCTN63545820) trial (15), which
was approved by the Ministry of Health of the
Netherlands and the institutional ethical boards of
the participating centers. Written informed consent
was obtained from all participants.
Subjects. The eligibility criteria and recruitment
practices of the NELSON trial have been described
in detail elsewhere (15). Brieﬂy, participants are all
current and former heavy smokers between the ages
of 50 and 75 years old with a smoking history of at
least 16.5 pack-years. Exclusion criteria for partici-
pating in the lung cancer screening trial were self-
reported moderate or bad health with inability to
climb 2 ﬂights of stairs, a recent chest CT, current
or past cancer, and body weight $140 kg.
We included subjects from 2 centers (N ¼
3,648). The derivation cohort included 1,834 males
from the University Medical Center in Groningen.
The validation cohort included 1,725 males and 89
females from the University Medical Center in
Utrecht. At baseline, participants in the NELSON
trial ﬁlled in a questionnaire on their current and
former smoking behavior.
CT scanning and calcium analysis. Subjects under-
went at baseline a volumetric chest CT in full
inspiration between January 2004 and December
2007. CTs were obtained without cardiac or respi-
ratory gating on 16-slice multidetector CT scanners
with a collimation of 16  0.75 mm. The derivation
cohort was scanned on a Sensation-16 CT (Siemens
Medical Solutions, Forchheim, Germany), whereas
the validation cohort was scanned on either an
Mx8000 or Brilliance-16P CT (Philips Medical
Systems, Cleveland, Ohio). Exposure settings
were adjusted according to body weight: 120 kVp
(<80 kg) or 140 kVp ($80 kg) both at 30 mAs,
yielding an effective dose of <0.9 and <1.6 mSv,
respectively. Axial images with a slice thickness of
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1 mm at 0.7-mm increment were reconstructed using
a smooth reconstruction ﬁlter (Siemens B30f, Philips
B-ﬁlter).
Reconstruction slice thickness for calcium quan-
tiﬁcation was 3.1 mm. Four slices were averaged with
1.4 mm increment. Calcium quantiﬁcation was
performed with dedicated, noncommercial, in-house
developed software: calciﬁcations in the coronary
arteries were automatically quantiﬁed based on the
algorithm described by Isgum et al. (16), and calci-
ﬁcations in the aorta were quantiﬁed as previously
described (17). Brieﬂy, a threshold of 130 Houns-
ﬁeld units in combination with 3-dimensional con-
nected component labeling was used to identify
potential calciﬁcations. Subsequently, aortic calciﬁ-
cations were extracted based on multiatlas-based
segmentation of the aorta, followed by a supervised
pattern recognition system detecting aortic calciﬁ-
cations based on spatial, size, and texture features.
Given the excellent agreement between automatic
and manual calcium scoring of aortic lesions in low-
dose CT (17), only outliers in aortic calcium scores
were inspected and manually corrected if needed.
Coronary calciﬁcations were extracted based on a
probabilistic coronary calcium map providing an a
priori probability for appearance of coronary calciﬁ-
cations on a chest CT scan, followed by a supervised
pattern recognition system detecting calciﬁcations
based on spatial and texture features. All coronary
calciﬁcations were inspected and manually corrected
if needed. Calciﬁcations were quantiﬁed in terms of
total calcium volume (mm3). Additionally, Agatston
score was calculated for coronary calciﬁcations.
Cardiovascular events. We retrieved physician-
diagnosed cause of death and hospital admission
diagnosis through linkage with the National Death
Registry and the National Registry of Hospital
Discharge Diagnoses. This linkage was performed
using a validated probabilistic method (18,19). All
deaths and hospital diagnosis are coded by medical
doctors; we did not adjudicate the hospital diagnosis
and causes of death. We included fatal and nonfatal
cardiovascular events that occurred between January
1995 and January 2008. All events were classiﬁed
using the 9th (discharge diagnoses) and 10th (cause
of death) revision of the International Classiﬁcation
of Diseases. Hypertensive disease (codes 401–405),
ischemic heart disease (codes 410–414), heart failure
(code 428), diseases of arteries, arterioles and cap-
illaries (codes 440–448), cerebrovascular disease
(codes 430–438), or other heart disease (code 429)
were included as cardiovascular events. Revascular-
ization procedures were not considered valid end-
points. Cardiovascular death prevailed over hospital
admissions. In case of multiple valid hospital ad-
missions the ﬁrst hospital discharge diagnosis was
used. A positive history for cardiovascular disease
was deﬁned as any cardiovascular event between
1995 and the CT (on average 10 years).
Derivation of the prediction model. Cox propor-
tional hazards analysis was used to predict 3-year
cardiovascular events (i.e., the average follow-up
time of the cohort). The prediction model was
derived from the center with most events (Gronin-
gen, 145 events). First, coronary calcium volume and
aortic calcium volume were truncated at the 99th
percentile because it is undesirable that prognostic
accuracy is inﬂuenced by biologically implausible
outliers. Second, imputation based on regression
techniques was performed in case of missing values
(20); coronary calcium volume was missing in 1,
aortic calcium volume in 2, smoking status in 3, and
pack-years in 7 subjects. Subsequently, a preliminary
model was ﬁtted using the pre-speciﬁed predictors
age, smoking status, smoking history, history of
cardiovascular disease, coronary calcium volume,
and aortic calcium volume. Also, the biologically
plausible interaction between age and calcium was
added to the model. In order to improve model
ﬁt, we determined the functional form to be used
for each continuous predictor by examining univar-
iate nonlinear restricted cubic spline transformations
(21). It showed that in our dataset a smoking
history >50 pack-years, coronary calcium volume
>1,500 mm3, and aortic calcium volume >4,000
mm3 had no added predictive value. Consequently,
smoking history, coronary calcium volume, and
aortic calcium volume were truncated at these cutoff
values. Next, the model was speciﬁed using backward
stepwise selection based on Akaike Information
Criterion (22), but no predictors were excluded. To
assess the proportional hazards assumption, correla-
tions between scaled Schoenfeld residuals for various
predictors and time were tested (23). Bootstrap
resampling was used to quantify the degree of over-
optimism of the model, which was consequently
corrected for by uniformly shrinking the regression
coefﬁcients by the same amount (24). Finally, a
nomogram was generated to illustrate the model.
The primary analysis was performed in all sub-
jects, because we believe that an absolute risk esti-
mate should also be applicable to subjects who
previously experienced a cardiovascular event.
Therefore, we included cardiovascular history as a
predictor in the model and did not exclude these
subjects from our analysis. Secondary analyses were
performed in subjects without cardiovascular history
(n ¼ 1,620, 106 events), in subjects with ischemic
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heart disease and cerebrovascular disease as outcome
event (n ¼ 1,834, 111 events), and using Agatston
score instead of coronary calcium volume (n ¼
1,834, 145 events).
Validation of the prediction model. The prediction
model was validated in males from the Utrecht
location (118 events). The 89 females were not
incorporated into the analysis as the variable sex was
not included in the prediction model due to the
absence of females in the derivation cohort. Impu-
tation based on regression techniques was per-
formed in case of missing values (20); smoking
status was missing in 3 subjects and pack-years was
missing in 7 subjects. Model discrimination and
calibration were evaluated to assess the performance
of the model. Discrimination is the ability of the
model to separate those with and without a
cardiovascular event, and was assessed by using C-
indexes (25). Calibration refers to the agreement
between the predicted risk and the observed values,
and was evaluated with the Grønnesby and Borgan
goodness-of-ﬁt test (26,27). Event-free survival was
calculated for 1-, 2-, and 3-year follow-up.
To illustrate the model, we evaluated several
cutoff values for high-risk by using receiver-
operating characteristic and Kaplan-Meier survival
analysis, although eventually the cutoff depends on
formal cost-effectiveness analysis. Nevertheless, we
aimed to illustrate the model at a cutoff value that
provided a sufﬁciently large number of correctly
predicted events at a reasonable number of referred
cases.
Because we used ungated CT, which over-
estimated coronary calcium scores compared to
gated CT (28,29), we simulated a systematic over-
estimation of coronary calcium volume of 100% in
the validation cohort by dividing the measured
coronary calcium volumes by 2. The number of
events incorrectly reclassiﬁed to the non–high-risk
subgroup was determined.
All analyses were performed with R statistical
software, version 2.10.2 (R Foundation for Statis-
tical Computing, Vienna, Austria).
RESULTS
Study population. The subjects in both cohorts were
about 60 years old and had smoked 38 pack-years.
Current and former smokers were about equally
present. A cardiovascular history was present in
214 (11.7%) subjects in the derivation cohort, and in
238 subjects (13.1%) of the validation cohort. During
follow-up 145 (11 fatal, 134 nonfatal) and 120
(7 fatal, 113 nonfatal) cardiovascular events occurred
in the derivation and validation cohort, respectively.
The majority of events were from ischemic heart
disease or cerebrovascular disease; 109 of 145 (75%)
in the derivation cohort and 74 of 120 (62%) in the
Table 1. Baseline Demographics of the Study Populations
Derivation Cohort
(n [ 1,834)
Validation Cohort
(n [ 1,814)
Age, yrs 59.2 (55.8–63.4) 60.0 (56.5–64.3)
Male 1,834 (100) 1,725 (95)
Current smoker 1,055 (57.5) 972 (53.6)
Former smoker 776 (42.3) 842 (46.3)
Pack-years, yrs 38.0 (28.0–46.2) 38.0 (29.7–49.5)
Time before CT*, yrs 10.1 (9.8–10.5) 9.8 (9.6–10.2)
Cardiovascular history 214 (11.7) 238 (13.1)
Time to event, yrs 2.82 (2.29–3.15) 3.07 (2.81–3.42)
Cardiovascular event 145 (7.9) 120 (6.6)
Ischemic heart disease or
cerebrovascular disease
109 (75.2) 74 (61.7)
Cardiovascular death 11 (0.6) 7 (0.4)
All-cause death 33 (1.8) 27 (1.5)
Coronary calcium volume, mm3 260 (36–944) 94 (4–536)
Aorta calcium volume, mm3 574 (123–1961) 465 (77–1579)
Values are median (25th to 75th interquartile range) or n (%). *The period prior to the screening computed
tomography (CT) for which data on cardiovascular history was collected.
Table 2. The Effect of the Predictors on the 3-Year Risk of Cardiovascular Events in the Derivation Cohort (n [ 1,834)
Predictor Beta Standard Error Wald Z p Value
Hazard Ratio
(95% Conﬁdence Interval)
Age (per 10 yrs) 0.218 0.174 1.25 0.21 1.24 (0.88–1.75)
Former smoker 0.729 0.185 3.95 <0.0001 0.48 (0.34–0.69)
Smoking history (per 10 pack-yrs) 0.219 0.088 2.49 0.0128 1.24 (1.05–1.48)
Cardiovascular history present 0.638 0.200 3.19 0.0014 1.89 (1.28–2.80)
Coronary calcium volume (per 500 mm3) 0.376 0.080 4.70 <0.0001 1.46 (1.25–1.70)
Aortic calcium volume (per 500 mm3) 0.096 0.033 2.92 0.0035 1.10 (1.03–1.18)
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validation cohort. Full details on the incident events
and mortality are provided in Online Table 1.
Overall, baseline survival was 0.976 (1 year), 0.955 (2
year), and 0.940 (3 year). The characteristics of the
derivation and validation cohort are summarized in
Table 1.
Derivation of the prediction model. On testing the
proportional hazards assumption, no statistically
signiﬁcant proportionality was found (p ¼ 0.48).
The interaction term between age and calcium
scores was not included in the ﬁnal model as it did
not improve the model ﬁt. The ﬁnal model included
age, smoking status, pack-years, history of cardio-
vascular disease, coronary calcium volume, and
aortic calcium volume as independent predictors.
Table 2 lists the regression coefﬁcients and the
hazard ratios of the predictors. The increase in
hazard ratios with increasing extent of coronary and
aortic calcium is further illustrated in Table 3.
Discrimination of the model in the derivation set
was good, showing a C-statistic of 0.74 (95% con-
ﬁdence interval [CI]: 0.70 to 0.78). Overoptimism
was found to be 3.4%, therefore, the coefﬁcients
were shrunk by a factor 0.966. The resulting
mathematical equation to calculate absolute indi-
vidual risk for a cardiovascular event is presented in
the supplement (Online Equation 1). The nomo-
gram for cardiovascular risk prediction is presented
in Figure 1.
Secondary analyses showed that a model in sub-
jects without a cardiovascular history had good
discrimination in the derivation cohort, showing a
C-statistic of 0.73 (95% CI: 0.68 to 0.78). When
the combined endpoint ischemic heart disease and
cerebrovascular disease were included as endpoints,
aortic calcium volume ended up being excluded
from the model. The discrimination of this model
was similarly good with a C-statistic of 0.73 (95%
CI: 0.68 to 0.78). Last, when Agatston score was
used instead of coronary calcium volume, the model
showed a C-statistic 0.74 (95% CI: 0.70 to 0.78).
Validation of the prediction model. In the validation
cohort discrimination remained good and yielded a
C-statistic of 0.71 (95% CI: 0.67 to 0.76). Cali-
bration of the model was good, without statistically
signiﬁcant differences between predicted and
observed values (goodness-of-ﬁt test, p ¼ 0.65).
The calibration plot is presented in the supplement
(Online Fig. 1). The individual risk can be calcu-
lated by using the nomogram presented in Figure 1.
We judged that the proportions of true positive,
false negative, and the total amount of referred
subjects was reasonable at a risk equal to or greater
than 6%, and will use this arbitrary cutoff for further
illustration. This cutoff was also the optimum in the
receiver-operating characteristic analysis and corre-
sponds favorably to a 10-year risk of 20%, which is
commonly used in cardiovascular medicine to deﬁne
high risk. The performance of the prediction model
at this and other cut-off values is presented in
Table 4. The characteristics of the resulting high-
risk males as identiﬁed by the model at the chosen
cutoff level at 6% are listed in Table 5. Compared to
subjects the model identiﬁed as non–high risk, the
subjects predicted to have high risk had substantial
higher coronary and aortic calcium volumes. The
probability for an event in the selected high-risk
subgroup was 12.2% (72 of 589), compared with
4.0% (46 of 1,136) in the non–high-risk subgroup.
Figure 2 shows the Kaplan-Meier survival curves for
both the high-risk and non–high-risk subgroup.
Simulated overestimation of coronary calcium vol-
ume. In the simulation with coronary calcium vol-
ume reduced by 50% the number of correctly
detected high-risk subjects dropped only slightly
from 72 to 66 whilst the proportion deﬁned as high
risk decreased from 34% to 30%, reducing the
number of false positives (Online Table 2).
D I SCUSS ION
This study shows that automated quantiﬁcation of
coronary and aortic calcium in lung cancer screening
CT scans, combined with few patient demographics
and smoking characteristics, can be used to predict
cardiovascular events and re-events. This
Table 3. HR for Varying Extent of Coronary and
Aortic Calcium Volumes*
Coronary calcium volume
100 mm3 1.08 (1.05–1.11)
250 mm3 1.22 (1.13–1.31)
500 mm3 1.48 (1.27–1.72)
1,000 mm3 2.18 (1.61–2.95)
$1,500 mm3 3.22 (2.05–5.07)
Aortic calcium volume
100 mm3 1.02 (1.00–1.03)
250 mm3 1.04 (1.01–1.07)
500 mm3 1.08 (1.02–1.15)
1,000 mm3 1.17 (1.04–1.33)
1,500 mm3 1.27 (1.06–1.53)
2,500 mm3 1.50 (1.10–2.04)
$4,000 mm3 1.90 (1.16–3.13)
Values are hazard ratio (95% conﬁdence interval). *In multivariate analysis
with age, smoking status, smoking history, and cardiovascular history.
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information, which is readily available in the
screening test, may be utilized in the screening of
current and former heavy smokers to identify those
with highest risk for cardiovascular events. These
subjects may beneﬁt most from targeted and
intensive primary and secondary preventive
strategies.
Implications for practice. Practically, when males
are identiﬁed as high-risk using CT-based
screening, initiation, and optimization of preven-
tive measures and intensiﬁcation of smoking
cessation efforts may be the most viable way
through which to improve subjects’ outcome. Pri-
mary and secondary preventive efforts are
Table 4. Approximation of the Performance of the Prediction Model in the Derivation Cohort at Various Cutoff Values for High Risk
3-Year Risk* True Positive False Negative True Negative False Positive PPV (%) NPV (%) High-Risky (%)
1% 118 0 2 1,605 6.9 100.0 99.9
2.5% 111 7 307 1,300 7.9 97.8 81.8
6% 72 46 1,100 507 12.4 96.0 33.6
10% 48 70 1,349 258 15.7 95.1 17.7
15% 34 84 1,474 133 20.4 94.6 9.7
20% 23 95 1,540 67 25.6 94.2 5.2
25% 15 103 1,566 41 26.8 93.8 3.3
Values are n or %. *Three-year risk cutoff value to divide high-risk and non–high-risk subjects. yPercentage of the screening population the model deﬁned as high risk
for a cardiovascular event within 3 years using to the corresponding cutoff value.
NPV ¼ negative predicted value; PPV ¼ positive predicted value.
Figure 1. Nomogram to Calculate Individual 3-Year Risk for a Cardiovascular Event
Patient characteristics are ﬁlled in and points earned are determined per variable. The sum of all points yields a total score, corresponding to a
3-year event-free survival is read of. A total of 21 points yields a cardiovascular risk over 6% (event-free survival below 0.94), classifying the
subject into the high-risk subgroup based on the cutoff value chosen in this study.
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recommended to reduce cardiovascular morbidity
and mortality (13,14). In particular, smoking
cessation signiﬁcantly reduces the risk for cardio-
vascular events and death, especially coronary heart
disease, within a short time period (30). While the
potential beneﬁts are promising, establishing their
magnitude and the cost-effectiveness of chest CT-
based screening for multiple diseases is beyond the
scope of this study and requires a formal outcome
study. Nevertheless, multiple disease screening is
an interesting concept and may increase the ben-
eﬁts of screening heavy smokers with a chest CT
beyond lung cancer (31).
Study population. Even though the discrimination
of the prediction model remains acceptable when
subjects with cardiovascular history are excluded, we
propose to include subjects with a prior cardiovas-
cular event for several reasons. First, even when a
subject has experienced a prior event, the risk for a
re-event differs substantially between individuals; in
our dataset, some subjects show a re-event risk of
4.5%, while others show a re-event risk of >20%
within 3 years. The latter subject may require more
thorough evaluation as to whether secondary pre-
vention can be optimized or whether changes in
management are needed. Second, the re-event may
occur at another location than the prior event (e.g.,
myocardial infarction in a subject with a history of
peripheral artery disease). Third, subjects who have
experienced a cardiovascular event may not receive
optimal secondary preventive measures or do not
show good medication adherence (32).
Study limitations. First, we note that the derivation
and validation cohort originate from the same lung
cancer screening trial. Nevertheless, the 2 locations
are situated in geographically distant parts of the
Netherlands, with substantial differences in popu-
lation density and migration rate. Furthermore, CT
scanners from different vendors were used in the
different locations. Second, calcium volume scores
may be inﬂuenced by the applied scanning protocol.
Ungated CT may lead to systematic overestimation
of coronary calcium (but not aortic calcium) due to
cardiac motion (28,29). However, while ungated
CT can not exclude coronary heart disease, it is
excellent for the detection of the high amounts of
calcium needed for our purpose of identifying high-
risk subject (12,29). Also, the weight-adjusted kVp
might have inﬂuenced the absolute calcium volume
score. Nevertheless, we showed that even a reduc-
tion of 50% (i.e., an overestimation of 100%) for
coronary calcium leads to only modest decrease in
the number of detected cases. Therefore, we expect
that both the lack of electrocardiography gating and
the differing kVp do not importantly inﬂuence the
model performance in this population. Third, it
would be advantageous to provide separate risk
predictions for cerebrovascular disease, coronary
heart disease, and aorta and peripheral arterial dis-
ease. However, our dataset lacked power for such
detailed subgroup analyses. Fourth, caution is
needed regarding the generalizability of our results
outside a lung cancer screening setting and to fe-
males, given that no females were included in our
derivation cohort. Last, our study may be limited by
a nonstandard cardiovascular disease endpoint as we
relied on the coded medical data from the national
registry to deﬁne patient history and cardiovascular
events. Furthermore, because we operated within
a lung cancer screening setting, conventional
Figure 2. Kaplan-Meier Survival Curves of Cardiovascular
Event-Free Survival in Non–High-Risk and High-Risk
Subgroups
The survival curves show a distinct difference in the event free
survival over a 3-year period between computed tomography–
based high-risk ($6%, dotted line) and non–high-risk
(<6%, solid line) males.
Table 5. Characteristics of the Model-Based High-Risk and Non–High-Risk Males
in the Validation Cohort
Non–High Risk (<6%) High Risk (‡6%)
Number of participants 1,136 (61.9) 589 (34.1)
3-yr cardiovascular risk, % 3.4 (2.4–4.5) 10.3 (7.7–16.3)
Age, yrs 58.6 (55.9–62.3) 62.9 (59.3–67.6)
Pack-yrs 34.2 (28.0–43.7) 43.7 (34.2–55.2)
Current smoker 544 (47.9) 375 (63.7)
Cardiovascular history 42 (3.7) 192 (32.6)
Cardiovascular events 46 (4.0) 72 (12.2)
Re-event* 4 (8.7) 34 (47.2)
Coronary calcium volume, mm3 27 (0–161) 863 (313–1834)
Aortic calcium volume, mm3 212 (33–666) 2,073 (775–4551)
Values are n (%) or median (25th to 75th interquartile range). *Proportion of cardiovascular events
occurring in subjects with any cardiovascular history.
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cardiovascular risk factors are mostly unknown.
Evidence is growing that arterial calciﬁcations can
predict cardiovascular disease independent from
smoking and traditional risk factors (33–35), which
is also supported by the good performance of our
model that is based on smoking details and calciﬁ-
cations. One has to realize that measuring risk
factors such as blood pressure and lipid levels is not
part of current lung cancer screening protocols, and
will signiﬁcantly alter the logistics and feasibility of
screening practice. Although the coded registry may
not be faultless, this national registry has been
validated and provides high-quality data. The pre-
sent study validates the prognostic value of vascular
calciﬁcations and clearly demonstrates the ability
of cardiovascular risk assessment from screening
chest CT.
CONCLUS IONS
We showed that automated quantiﬁcation of coro-
nary and aortic calcium in a CT-based lung cancer
screening setting can be used to predict events and
re-events in a population of current and former
heavy smokers. This additional information on
cardiovascular disease, which is readily available in
the screening test, may enhance the cost-
effectiveness of CT screening in heavy smokers,
although a randomized clinical trial is needed to
establish the exact magnitude.
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